Puromycin (CL13900) 2HCl

Catalog No.S7417

For research use only.

Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.

Puromycin (CL13900) 2HCl Chemical Structure

CAS No. 58-58-2

Selleck's Puromycin (CL13900) 2HCl has been cited by 97 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Other Antineoplastic and Immunosuppressive Antibiotics Products

Biological Activity

Description Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.
In vitro

The antibiotic puromycin is produced by the actinoniycete, Streptornyces alboniger, and has been used as a tool for studying protein synthesis in a number of systems. [1] Puromycin can be used for the selection of recombinant cells from noncultured cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K562 NFf6NGFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkDJO|IhcA>? NVnmclhZT3Kxd4ToJIlvcGmkaYTpc44hd2ZiZH;4c5J2[mmlaX6tdoV{cXO2YX70JIh2dWGwIFu1OlIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OD1{Nj64N{DPxE1w M3L2ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{GzN|A4Lz5zOEOxN|MxPzxxYU6=
HepG2 NWi0NXFOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF[3WGk4OiCq MYfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNlMh|ryPLh?= NXzSbVl1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNVM{ODdpPkG4N|E{OzB5PD;hQi=>
K562 NVjKTHJbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2nqblczKGh? MnrUS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT|U3OiClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNlIh|ryPLh?= Ml3uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|MUOzNFcoRjF6M{GzN|A4RC:jPh?=
HepG2 NX7i[3pqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXW3NkBp NWH3RVB6T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjJzIN88UU4> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDVzMkm4OEc,OTh3MUK5PFQ9N2F-
Huh7 M4P4NGN6fG:2b4jpZ4l1gSCjc4PhfS=> MofDUm9XSVKWSWO6JGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIhmeGG2b3PlcIx2dGG{IHPhdoNqdm:vYTDj[YxtKGyrbnWgLGh2cDdrLDDDR|UxRTZwNkOg{txONg>? NHvqbYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW3PVc5Oyd-MUi1O|k4QDN:L3G+
HEK239 MnvzR5l1d3SxeHnjbZR6KGG|c3H5 MVG3NkBp M3qzcGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{KzPUBk\WyuczDh[pRmeiB5MjDodpMh[nliQXzhcYFzKGKudXWgZZN{[XluIFnDOVA:OC52MjFOwG0v NYTJUlJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1OVgxPjBpPkKwOVU5ODZyPD;hQi=>
J774A1 MXrDfZRwfG:6aXPpeJkh[XO|YYm= MmHnR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgTlc4PEFzIHPlcIx{KGK7IITyfZBidiCkbIXlJIV5[2y3c3nvckBie3OjeTygTWM2OD1zMDFOwG0v M3zyWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUO0OlM3Lz5{MkmzOFY{PjxxYU6=
KB3-1 M3Wyc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFvjZng4OiCqcoO= MYnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDLRlMuOSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4zOSEQvF2u M2jCNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{GzN|A4Lz5zOEOxN|MxPzxxYU6=
HepG2/Dox MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn\LO|IhcHK| MXnHdo94fGhiaX7obYJqfGmxbjDv[kBufWy2aXTyeYchemW|aYP0ZY51KGi3bXHuJGhmeEd{L1TvfEBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxKD1iMkCuNkDPxE1w M4\iZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUGyPVg1Lz5zOEWxNlk5PDxxYU6=
HEK293 NEjheG5EgXSxdH;4bYNqfHliYYPzZZk> NET2XW04OiCqcoO= MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KHKnc3H6eZJqdi2kYYPl[EBxdGG2ZTDy[YFl\XJiYX7hcJl{cXNuIFnDOVAhRSByLkO2NUDPxE1w M3TWZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWxOVM4Lz5{Nk[1NVU{PzxxYU6=
HEK293 NEjJXVREgXSxdH;4bYNqfHliYYPzZZk> NXvuTVk2PzJiaILz NWK4e243S3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjN3MEWg{txONg>? Mn65QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlMoRjJ5ME[wO|Y{RC:jPh?=
A549 MYPDfZRwfG:6aXPpeJkh[XO|YYm= NFHrcVBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{NCCLQ{WwJF0hOC54IN88UU4> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB6OUKxOEc,OjdyOEmyNVQ9N2F-
PC3 MoqyR5l1d3SxeHnjbZR6KGG|c3H5 MkPUR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzMEBKSzVyIE2gNE44KM7:TT6= MmryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyOEmyNVQoRjJ5MEi5NlE1RC:jPh?=
HEK293 NHjvbHFEgXSxdH;4bYNqfHliYYPzZZk> NVrH[4xsS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOC5yMECzOUDPxE1w M3vNb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkGyNFcxLz5{N{KxNlA4ODxxYU6=
HEK293 NHjFdGtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF;vPYw4OiCqcoO= NF;TSHlIem:5dHigbY5pcWKrdHnvckBw\iCKRVuyPVMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGDy[ZN1d0KudXWgd5RicW6rbnegZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR|UxKD1iMD6zOkDPxE1w MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDByMUC2O{c,OjhyMEGwOlc9N2F-
HEK293 NX2zRo1nT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFr0Ro1Iem:5dHigbY5pcWKrdHnvckBw\iCKRVuyPVMh[2WubIOsJGlEPTBiPTCwMlM6QSEQvF2u NILZeYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESwNFI{OSd-Mki0NFAzOzF:L3G+
SU-DHL10 M{LuXWN6fG:2b4jpZ4l1gSCjc4PhfS=> NUfDcpdtPzJiaILz M3znSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNWNUSKTEGwJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2cnWtS4xwKGy3bXnu[ZNk\W62IHHzd4F6NCCFQ{WwJF0hOC5zMTFOwG0v MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV{M{GwN{c,Ojh3MkOxNFM9N2F-
MIAPaCa2 Mm[1R5l1d3SxeHnjbZR6KGG|c3H5 M3\IWlczKGi{cx?= NIr2dWlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOUUGSYVPhNkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdILlMWdtdyCudX3pcoV{[2WwdDDhd5NigSxiQ1O1NEA:KDBwMjFOwG0v NHLpXng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEWyN|ExOyd-Mki1NlMyODN:L3G+
MDA-MB-231 M1fEOGN6fG:2b4jpZ4l1gSCjc4PhfS=> NH\0Uno4OiCqcoO= NIPBfpFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JIF{e2G7LDDDR|UxKD1iMD60PEDPxE1w MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV{M{GwN{c,Ojh3MkOxNFM9N2F-
HEK293 MmXlR5l1d3SxeHnjbZR6KGG|c3H5 MmTJO|IhcHK| NXq4XZBqS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IFHsZY1ieiCkbIXlJIF{e2G7LDDJR|UxKD1iMD60OkDPxE1w MlW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5N{S0NlcoRjJ6N{e0OFI4RC:jPh?=
HL60 MUTBcpRqeGG{YYPpeIlkKGG|c3H5 Mnf3O|IhcHK| MkjuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFXDOVAhRSByLkC1OUDPxE1w MkXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6MEOwOFcoRjJ6OECzNFQ4RC:jPh?=
MOLT4 M3HjUmFvfGmyYYLhd4l1cWNiYYPzZZk> NES2NG84OiCqcoO= NHrVXYVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUHQ1KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGVEPTBiPTCwMlE4KM7:TT6= M17OO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OECzNFQ4Lz5{OEiwN|A1PzxxYU6=
Vero M{jKXGN6fG:2b4jpZ4l1gSCjc4PhfS=> NVf6XoIyPzJiaILz Ml\iR5l1d3SxeHnjbZR6KGGpYXnud5QhSW[{aXPhckBoemWnbjDtc45s\XliVnXyc{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFPDOVAhRSB{Lkig{txONg>? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhyM{C0O{c,Ojh6MEOwOFc9N2F-
HEK293 MWnDfZRwfG:6aXPpeJkh[XO|YYm= M3q2S|czKGi{cx?= MlLjR5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|IHHmeIVzKDd{IHjyd{BjgSC{ZYPhfpVzcW5iZInlJIJie2WmIHHzd4F6NCCLQ{WwJF0hOC52NTFOwG0v M2roPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkO2OFkzLz5{OUKzOlQ6OjxxYU6=
HEK293T M{O1cWN6fG:2b4jpZ4l1gSCjc4PhfS=> M1fyT|czKGi{cx?= M1\rdGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhGUzJ7M2SgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hemWjZ3XueEBj[XOnZDDseY1qdmW|Y3XuZ4Uh[XO|YYmsJGNEPTBiPTCwMlQzKM7:TT6= M3nQWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[5OVc2Lz5{OUS2PVU4PTxxYU6=
HCT8 MXvBcpRqeGG{YYPpeIlkKGG|c3H5 MUS0PEBpenN? MXLBcpRqeGG{YYPpeIlkKGGldHn2bZR6KGGpYXnud5QhS3K7cITvd5BwemmmaYXtJJBien[3bTDCS2YhcW6oZXP0[YQhcW5iaIXtZY4hUEOWODDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBHUVSFL1TBVGkhe3SjaX7pcoch[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5MEBGSzVyIE2gNE42PSEQvF2u MmTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nkm1O|UoRjJ7NE[5OVc2RC:jPh?=
HCT8 MnfCRY51cXCjcnHzbZRq[yCjc4PhfS=> MmD1OFghcHK| MXfBcpRqeGG{YYPpeIlkKGGldHn2bZR6KGGpYXnud5QhS3K7cITvd5BwemmmaYXtJJBien[3bTDTVGwhcW6oZXP0[YQhcW5iaIXtZY4hUEOWODDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBHUVSFL1TBVGkhe3SjaX7pcoch[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5MEBGSzVyIE2gNE43KM7:TT6= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4OUW3OUc,Ojl2Nkm1O|U9N2F-
HepG2 NIPVPGtEgXSxdH;4bYNqfHliYYPzZZk> M{fQcVczKGi{cx?= NF\SW5lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bz\WGpZX70JIJie2WmIHz1cYlv\XOlZX7j[UBie3OjeTygR2M2OCB;IECuPFMh|ryPLh?= NH3YeYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2PVU4PSd-Mkm0Olk2PzV:L3G+
HCT8 NX\6e4FsS3m2b4TvfIlkcXS7IHHzd4F6 NHvVT|dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1R6IHPlcIx{NCCHQ{WwJF0hPi5zIN88UU4> M4PJVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[5OVc2Lz5{OUS2PVU4PTxxYU6=
HEK293 MWTDfZRwfG:6aXPpeJkh[XO|YYm= NFLWNIU4OiCqcoO= NYLWZmViS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCpcn;3eIgh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyIE2gNE41PiEQvF2u MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV|M{[xNUc,Ojl3M{O2NVE9N2F-
HEK293 MYfDfZRwfG:6aXPpeJkh[XO|YYm= MmTjO|IhcHK| MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDISWszQTNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJJme2G8dYLpckBlgWViYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC52IN88UU4> Ml72QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7NkmyOlIoRjJ7OU[5NlYzRC:jPh?=
A549 Mn;HR5l1d3SxeHnjbZR6KGG|c3H5 MVO0PEBpenN? MofRR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOsJGlEPTBiPTCwMlMh|ryPLh?= NH;XXZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MESxPFc3Oyd-M{C0NVg4PjN:L3G+
PC3 M3;kdmN6fG:2b4jpZ4l1gSCjc4PhfS=> MXO0PEBpenN? MmPHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czygTWM2OCB;IECuN{DPxE1w NIDHXHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MESxPFc3Oyd-M{C0NVg4PjN:L3G+
Assay
Methods Test Index PMID
Western blot Cyclin D1 / CDK4 ; PARP / Bcl-xL / Bcl-2 / p-Akt / Akt ; p53 / p21 / c-Myc 31022952
Growth inhibition assay Cell viability 31022952

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 544.43
Formula

C22H29N7O5.2HCl

CAS No. 58-58-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)NC(=O)C(CC4=CC=C(C=C4)OC)N)O.Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Puromycin (CL13900) 2HCl | Puromycin (CL13900) 2HCl supplier | purchase Puromycin (CL13900) 2HCl | Puromycin (CL13900) 2HCl cost | Puromycin (CL13900) 2HCl manufacturer | order Puromycin (CL13900) 2HCl | Puromycin (CL13900) 2HCl distributor